159992 创新药
已收盘 12-19 15:00:00
资讯
新帖
简况
招商证券：医药板块创新药产业链仍是主线 重点关注小核酸等技术方向
智通财经 · 10:17
招商证券：医药板块创新药产业链仍是主线 重点关注小核酸等技术方向
九典制药：正在全面转型创新药研发，迅速布局创新药
第一财经 · 12-18 22:13
九典制药：正在全面转型创新药研发，迅速布局创新药
奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察
华夏时报网 · 12-18 15:03
奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察
创新药概念逆市上扬 石药集团(01093)午后升幅扩至近6%
金吾财讯 · 12-18 13:21
创新药概念逆市上扬 石药集团(01093)午后升幅扩至近6%
石药集团早盘涨近5% 旗下石药创新拟在香港主板上市 融资支持创新药业务发展
智通财经 · 12-18 11:12
石药集团早盘涨近5% 旗下石药创新拟在香港主板上市 融资支持创新药业务发展
中国创新药崛起背后的“加减法”：为真创新提供真支持
三里河 · 12-16 20:38
中国创新药崛起背后的“加减法”：为真创新提供真支持
利空突袭，5倍创新药牛股大幅杀跌，股价腰斩
21世纪经济报道 · 12-16 18:39
利空突袭，5倍创新药牛股大幅杀跌，股价腰斩
创新药概念再度走低 诺诚健华(09969.HK)跌超5%
每日经济新闻 · 12-16
创新药概念再度走低 诺诚健华(09969.HK)跌超5%
创新药保障“最后一公里”待解
21世纪经济报道 · 12-16
创新药保障“最后一公里”待解
【ETF动向】12月15日华宝恒生港股通创新药精选ETF基金跌3.32%，份额增加1.42亿份
证券之星 · 12-16
【ETF动向】12月15日华宝恒生港股通创新药精选ETF基金跌3.32%，份额增加1.42亿份
康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib 纳入突破性治疗品种名单
智通财经 · 12-15
康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib 纳入突破性治疗品种名单
19种创新药“入编”商保目录 险企仍面临定价、合规等挑战
21世纪经济报道 · 12-15
19种创新药“入编”商保目录 险企仍面临定价、合规等挑战
和讯投顾冯禄顺：1213创新药接下来怎么走
中金财经 · 12-13
和讯投顾冯禄顺：1213创新药接下来怎么走
诺华肾病治疗创新药诺锐达 （盐酸阿曲生坦片）在京东健康全网首发
证券日报网 · 12-12
诺华肾病治疗创新药诺锐达 （盐酸阿曲生坦片）在京东健康全网首发
创新药企扎堆港股IPO
21世纪经济报道 · 12-12
创新药企扎堆港股IPO
重磅官宣，康方生物大涨6.8%！创新药龙头集体提振，高弹性港股通创新药ETF（520880）转涨拉升逾1%
新浪基金 · 12-12
重磅官宣，康方生物大涨6.8%！创新药龙头集体提振，高弹性港股通创新药ETF（520880）转涨拉升逾1%
475亿A股药企，要去港股找钱！搞创新药刚亏上亿
市场资讯 · 12-12
475亿A股药企，要去港股找钱！搞创新药刚亏上亿
【券商聚焦】交银国际：创新药增量支付空间持续扩大
金吾财讯 · 12-12
【券商聚焦】交银国际：创新药增量支付空间持续扩大
康哲药业脑卒中治疗领域重磅创新药注射用Y-3中国NDA获受理
智通财经 · 12-11
康哲药业脑卒中治疗领域重磅创新药注射用Y-3中国NDA获受理
西部证券：2026年创新药行情将转变为“数据为王” 期待全球多中心临床实验数据读出催化
智通财经 · 12-11
西部证券：2026年创新药行情将转变为“数据为王” 期待全球多中心临床实验数据读出催化
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.855,"timestamp":1766127801000,"preClose":0.842,"halted":0,"volume":538012276,"delay":0,"changeRate":0.0154,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":0.013,"latestTime":"12-19 15:00:00","open":0.844,"high":0.861,"low":0.842,"amount":460000000,"amplitude":0.0226,"askPrice":0.856,"askSize":33601,"bidPrice":0.855,"bidSize":11051,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":0.842,"symbolType":"fund","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":0.926,"lowLimit":0.758,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.441702,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992/wiki","defaultTab":"wiki","newsList":[{"id":"2592131496","title":"招商证券：医药板块创新药产业链仍是主线 重点关注小核酸等技术方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2592131496","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592131496?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:17","pubTimestamp":1766110668,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券发布研报称，2026年医药板块在创新出海持续兑现、医疗内需分化的产业趋势下，有望出现结构行情。创新药产业链仍是主线，除观察二代IO、减重、ADC板块的临床数据外，尤其关注小核酸技术方向的加速发展；同时关注CXO、上游、原料药中具备景气度与业绩兑现的公司。创新及药品产业链CXO：在2025年以来，外需CXO业绩逐步兑现，分子类型持续革新带来新的产业机会；内需CRO需求结构性改善，新签订单持续增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK0188","BK1515","BK1564","BK0010","BK1574","09939","600999","BK1147","BK0276","BK0012","BK0183","BK0028","06978","BK1161","06099","159938"],"gpt_icon":0},{"id":"2592902107","title":"九典制药：正在全面转型创新药研发，迅速布局创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902107","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592902107?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:13","pubTimestamp":1766067180,"startTime":"0","endTime":"0","summary":"九典制药在机构调研时表示，公司目前正在全面转型创新药研发，采用“多个研发中心+多种药物形式+多种合作模式”策略迅速布局创新药。(本文来自第一财经)\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfvmf2970774.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfvmf2970774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","BK0239","06978","300705","BK1161"],"gpt_icon":0},{"id":"2592201369","title":"奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2592201369","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592201369?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:03","pubTimestamp":1766041380,"startTime":"0","endTime":"0","summary":"12月15日，生物医药公司诺诚健华宣布，其核心产品奥布替尼用于治疗系统性红斑狼疮（SLE）的IIb期临床研究达到主要终点，并已获国家药品监督管理局批准开展Ⅲ期临床试验。这一进展虽标志着该药在开拓自身免疫疾病这一巨大新市场的道路上迈出关键一步，但其通往成功商业化的道路仍布满不确定性，或将面临来自临床试验、市场竞争及公司战略的多重严峻挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595356395.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595356395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","159992","SLE","06978","09969","688428","BK1161","BK1574","BK4077"],"gpt_icon":0},{"id":"2592513924","title":"创新药概念逆市上扬 石药集团(01093)午后升幅扩至近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592513924","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592513924?lang=zh_cn&edition=full","pubTime":"2025-12-18 13:21","pubTimestamp":1766035316,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念逆市上扬，石药集团 升5.98%，药明生物升1.97%，药明合联升1.56%，先声药业升1.51%，药明康德升1.28%。开源证券指出，当前纳入医保+商保的创新药大多处于未放量以及低基数阶段，随着医保支持创新药的政策红利持续释放，我们认为纳入双目录的创新药收入有望快速提升，患者有望持续受益，同时相关创新药企也随之迎来弹性增长。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971799","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","02269","159992","LU1688375341.USD","LU1794554557.SGD","LU0052750758.USD","BK1574","LU0181495838.USD","SG9999002463.SGD","LU0140636845.USD","02268","06978","BK1515","LU0856984785.SGD","LU1242518857.USD","LU3063872942.SGD","LU1807302812.USD","BK1589","LU1152091754.HKD","LU1226287792.SGD","IE00B031HY20.USD","BK1583","LU0307460666.USD","IE0008369823.USD","LU1328277881.USD","LU1226287875.USD","LU1242518931.SGD","LU1813983027.USD","IE00BZ08YS42.EUR","LU0348825331.USD","LU1008478684.HKD","IE00B5MMRT66.SGD","BK1191","LU0315179316.USD","LU0588546209.SGD","02096","SG9999002562.SGD","LU0320764599.SGD","02359","IE00BZ08YT58.USD","IE00B543WZ88.USD","LU1046422090.SGD","LU0039217434.USD","IE00BZ08YR35.GBP","LU0348735423.USD","LU0572944931.SGD","01093","LU0051755006.USD","LU0456827905.SGD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2592257999","title":"石药集团早盘涨近5% 旗下石药创新拟在香港主板上市 融资支持创新药业务发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2592257999","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592257999?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:12","pubTimestamp":1766027520,"startTime":"0","endTime":"0","summary":"石药集团(01093)早盘涨近5%，截至发稿，涨4.79%，报7.88港元，成交额3.96亿港元。消息面上，12月10日，石药创新首次向港交所递交招股书，拟在香港主板上市。公开资料显示，石药创新由石药集 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251218/c673306787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2591984365","title":"中国创新药崛起背后的“加减法”：为真创新提供真支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2591984365","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591984365?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:38","pubTimestamp":1765888691,"startTime":"0","endTime":"0","summary":"2025年的最后一个月，外界期待已久的医保商保“双目录”对外公布。值得关注的是，新版国家医保目录里新增了111种5年内新上市药品，50种为1类新药，无论是比例还是数量，都创历年新高。这背后，医保基金正成为中国创新药产业发展的关键支撑之一，为“真创新”提供“真支持”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593227929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1574","159992","BK1161"],"gpt_icon":0},{"id":"2591498558","title":"利空突袭，5倍创新药牛股大幅杀跌，股价腰斩","url":"https://stock-news.laohu8.com/highlight/detail?id=2591498558","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591498558?lang=zh_cn&edition=full","pubTime":"2025-12-16 18:39","pubTimestamp":1765881540,"startTime":"0","endTime":"0","summary":" 昔日5倍大牛股，连日遭遇疯狂抛售。 12月15日，一品红的股价走势上演了戏剧性一幕：开盘即大幅下探，短短半小时内便触及20%跌停线，12月16日继续大幅下挫跌超10%，截至收盘报33.42元/股，市值缩水至150亿元左右，创近半年新低。 该股从去年9月底到今年7月，涨幅超过500%，但随后一路走弱，股价较最高位已经腰斩。年初至今涨幅回落至100%内。 就在12月15日晚，一品红还发布了利好公告，公司拟以集中竞价交易方式回购股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2025-12-16/doc-inhaywrc3128345.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-12-16/doc-inhaywrc3128345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","159992","BK1574"],"gpt_icon":0},{"id":"2591565672","title":"创新药概念再度走低 诺诚健华(09969.HK)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591565672","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591565672?lang=zh_cn&edition=full","pubTime":"2025-12-16 11:21","pubTimestamp":1765855266,"startTime":"0","endTime":"0","summary":"每经AI快讯，创新药概念股再度走低，截至发稿，诺诚健华(09969.HK)跌5.09%，报12.86港元；石药集团(01093.HK)跌3.99%，报7.21港元；信达生物(01801.HK)跌3.36%，报79港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163592831521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163592831521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK0239","06978","BK1161","688428","BK1574","159992"],"gpt_icon":0},{"id":"2591342678","title":"创新药保障“最后一公里”待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2591342678","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591342678?lang=zh_cn&edition=full","pubTime":"2025-12-16 07:00","pubTimestamp":1765839600,"startTime":"0","endTime":"0","summary":"年末，国家医保局与人力资源社会保障部同步发布新版国家医保目录及首版《商保创新药目录》，标志着我国医疗保障体系正式迈入“基本医保+商业健康险”双轮驱动的新阶段。这一结构性调整，不仅关乎行业格局，更直接触及每一位患者对前沿治疗方式的期待与焦虑。以商保承接高值创新药支付，是构建多层次医疗保障体系的关键拼图，旨在让患者面对重疾时多一份选择。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-16/doc-inhaxvcp1674477.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-16/doc-inhaxvcp1674477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","06978","BK1161"],"gpt_icon":0},{"id":"2591627189","title":"【ETF动向】12月15日华宝恒生港股通创新药精选ETF基金跌3.32%，份额增加1.42亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591627189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591627189?lang=zh_cn&edition=full","pubTime":"2025-12-16 06:32","pubTimestamp":1765837925,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日，华宝恒生港股通创新药精选ETF基金（520880）跌3.32%，成交额2.97亿元。当日份额增加了1.42亿份，最新份额为41.48亿份，近20个交易日份额增加3.66亿份。当日资金净流出2322.67万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为21.65亿元。华宝恒生港股通创新药精选ETF基金跟踪标的为恒生港股通创新药精选指数，成立（2025-06-27）以来超额回报为-2.79%，近一个月超额回报为-0.09%，管理人为华宝基金公司，基金经理为丰晨成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600003764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","BK1161","159992"],"gpt_icon":0},{"id":"2591264308","title":"康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib 纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2591264308","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591264308?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:49","pubTimestamp":1765799362,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，集团旗下德镁医药有限公司拥有相关许可权利的创新口服JAK1抑制剂povorcitinib已获中国国家药品监督管理局药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节段型白癜风。Povorcitinib目前正在海外若干国家进行非节段型白癜风、中重度化脓性汗腺炎和结节性痒疹的3期临床试验。本次该产品获纳入突破性治疗药物品种名单，有望加速其在中国大陆的研发与审评进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BMCWC346.EUR","SG9999004220.SGD","BK1574","BK1161","BK1593","IE00BYV24P56.USD","IE00BGHQDM52.EUR","06978","IE00BVYPNQ40.USD","00867","BK1191","SG9999015986.USD","SG9999015952.SGD","SG9999015978.USD","SG9999015945.SGD","LU2488822045.USD","IE00BVYPNP33.GBP","159992"],"gpt_icon":0},{"id":"2591100736","title":"19种创新药“入编”商保目录 险企仍面临定价、合规等挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2591100736","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591100736?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:09","pubTimestamp":1765793340,"startTime":"0","endTime":"0","summary":" 12月13日，全国医疗保障工作会议在北京召开。会议明确提出，2026年要支持商业健康保险发展，健全多层次医疗保障体系，并特别强调要“积极落地商保创新药品目录”，在个人充分授权和确保数据安全基础上，为有需要的商业健康保险产品提供“医保+商保”一站式清分结算服务。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/insurance/bxdt/2025-12-15/doc-inhawtsc3977664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxdt/2025-12-15/doc-inhawtsc3977664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2591639477","title":"和讯投顾冯禄顺：1213创新药接下来怎么走","url":"https://stock-news.laohu8.com/highlight/detail?id=2591639477","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591639477?lang=zh_cn&edition=full","pubTime":"2025-12-13 15:26","pubTimestamp":1765610765,"startTime":"0","endTime":"0","summary":"12月13日，我们来解读一下创新药板块。创新药已经连续下跌好多天了，那么这个方向有没有可能在这个地方形成一个双底的结构呢？ 朋友们可以看到，创新药板块在经历了一波下跌之后，出现了反弹，现在又跌到了前期的低点附近。 我之前给大家说过，创新药这个方向的反弹就是我们跑路的机会。 今天，也就是周五，出现了一根金针探底的小阴线，探了一个底。 所以，这个方向我们只能小反弹，谨慎参与。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20251213/31864360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","159992","06978","BK1161"],"gpt_icon":0},{"id":"2590570595","title":"诺华肾病治疗创新药诺锐达 （盐酸阿曲生坦片）在京东健康全网首发","url":"https://stock-news.laohu8.com/highlight/detail?id=2590570595","media":"证券日报网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590570595?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:09","pubTimestamp":1765534140,"startTime":"0","endTime":"0","summary":"本报讯(记者袁传玺)12月12日，诺华公司旗下创新药物诺锐达(盐酸阿曲生坦片)在京东健康线上首发。该药物是中国首个获批、用于降低有疾病快速进展风险的原发性免疫球蛋白A肾病(IgA肾病)成人患 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251212/c673167943.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251212/c673167943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2590457696","title":"创新药企扎堆港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590457696","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590457696?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:45","pubTimestamp":1765525500,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月以来，港股生物医药板块IPO市场热度持续攀升：嘉和生物、翰思艾泰、明基医院、华生物相继通过聆讯，和美药业、高光制药、石药创新、君赛生物陆续递交上市申请，中国证监会国际合作司亦于近期披露英硅智能境外发行上市的备案通知书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-12/doc-inhaprxm5183321.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-12/doc-inhaprxm5183321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","159992","BK1161","03378"],"gpt_icon":0},{"id":"2590781875","title":"重磅官宣，康方生物大涨6.8%！创新药龙头集体提振，高弹性港股通创新药ETF（520880）转涨拉升逾1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590781875","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590781875?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:37","pubTimestamp":1765521420,"startTime":"0","endTime":"0","summary":"12月12日午后，港股通创新药板块回暖，高弹性港股通创新药ETF翻红后持续拉升，现涨超1%，今日有望终结日线4连阴形态。值得关注的是，本周520880迎来“抄底”资金增仓，累计净申购额超1.3亿元。 成份股方面，权重龙头股康方生物领涨逾6.8%，信达生物涨超2%，百济神州涨逾1%。“同类最大港股通创新药ETF”：截至11月30日，港股通创新药ETF规模21.42亿元，上市以来日均成交4.58亿元，在跟踪同指数的2只ETF中规模最大、流动性最优。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-12/doc-inhapmrm5749076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0417516902.SGD","LU2488822045.USD","BK1574","IE00B5MMRT66.SGD","LU2778985437.USD","LU1961090484.USD","LU0540923850.HKD","BK1161","LU0348825331.USD","LU2399975544.HKD","IE00BPRC5H50.USD","09926","LU0634319403.HKD","LU0348735423.USD","LU0348783233.USD","520880","LU0348784397.USD","LU0417516571.SGD","LU0561508036.HKD","LU0348767384.USD","LU2476274720.SGD","06978","LU2476274308.USD","159992","LU0348827113.USD","LU1720050803.USD","LU0417516738.SGD","LU0348766576.USD","LU1794554557.SGD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2590357886","title":"475亿A股药企，要去港股找钱！搞创新药刚亏上亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2590357886","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590357886?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:23","pubTimestamp":1765520580,"startTime":"0","endTime":"0","summary":" 155亿身家的医药富豪，又要去港股上市了。 12月10日，国内知名制药企业石药集团旗下的石药创新制药股份有限公司，正式在港交所递交招股书，准备赴港上市。据招股书披露，2025年11月，石药创新以11亿人民币对价，从恩必普药业收购巨石生物额外29%的股权。收购后，石药创新于巨石生物的所有权权益增至80%。 从业绩来看，新诺威的赴港上市的背后，是传统业绩的失速，以及创新药转型的阵痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/2025-12-12/doc-inhapmrm5746118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1574","BK1161","399300","159982"],"gpt_icon":0},{"id":"2590233595","title":"【券商聚焦】交银国际：创新药增量支付空间持续扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2590233595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590233595?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:02","pubTimestamp":1765501348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资加大创新药布局的大方向不变。该机构指，本周医保+商保双目录落地，医保谈判新增品种成功率创近年新高，续约品种降价幅度相对温和。该机构认为商保资金的引入将为创新药支付带来重要增量资金，进一步优化多元支付体系。该机构看好医保新纳入品种/适应症在2026年的销售放量，以及首版商保目录的实际执行和支付情况。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971425","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU1951186391.HKD","LU2778985437.USD","LU0359202008.SGD","BK1161","01093","LU1242518931.SGD","LU0880133367.SGD","LU2328871848.SGD","LU0181495838.USD","03329","HK0000165453.HKD","01877","LU2097828631.EUR","LU0516423091.SGD","LU2097828557.USD","09926","LU2242644610.SGD","LU0348766576.USD","LU0359201612.USD","LU0043850808.USD","02142","LU2097828714.EUR","LU0540923850.HKD","LU1969619763.USD","LU0456827905.SGD","01801","09995","SG9999002463.SGD","06978","LU1226287529.USD","LU1961090484.USD","LU2039709279.SGD","02616","LU0708995583.HKD","06160","LU1993786604.SGD","IE00B0JY6N72.USD","LU1794554557.SGD","159992","LU0067412154.USD","01177","06185","09688","LU0417516738.SGD","02269","SG9999004220.SGD","LU1770034418.SGD","LU0502904849.HKD","BK1588"],"gpt_icon":0},{"id":"2590710590","title":"康哲药业脑卒中治疗领域重磅创新药注射用Y-3中国NDA获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590710590","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590710590?lang=zh_cn&edition=full","pubTime":"2025-12-11 19:34","pubTimestamp":1765452840,"startTime":"0","endTime":"0","summary":"2025年12月11日，康哲药业(00867)宣布，用于治疗急性缺血性卒中的1类创新药注射用Y-3(拟定中文通用名：注射用洛贝米柳)的新药上市许可申请(NDA)已获得中国国家药品监督管理局(NMPA)受理。注 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251211/c673141042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2590560279","title":"西部证券：2026年创新药行情将转变为“数据为王” 期待全球多中心临床实验数据读出催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2590560279","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590560279?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:15","pubTimestamp":1765437350,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西部证券发布研报称，展望2026年，创新药的行情将从“BD为王”转变为“数据为王”。临床数据中，全球多中心临床实验的数据读出，将是2026年的最值得期待的催化，该行相信2026依旧是创新药数据精彩纷呈的一年，也是投资创新药更有魅力的环节。BD方面，2025年中国药企license-out数量呈现快速增长趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK1161","06978","002673","BK1574","BK0276","159992","BK0028","BK0183"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766134475423,"stockEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.0518},{"period":"3month","weight":-0.1256},{"period":"6month","weight":0.0865},{"period":"1year","weight":0.1662},{"period":"ytd","weight":0.208}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}